ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2396 • ACR Convergence 2023

    Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis

    Jean-Charles Mourot1, Sai Yan Yuen2, Mihaela Popescu3 and Nicolas Richard4, 1Université de Montréal, Mont-Royal, QC, Canada, 2Maisonneuve-Rosemont Hospital, Mont-Royal, QC, Canada, 3Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, 4Hopital Maisonneuve Rosemont, Montreal, QC, Canada

    Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US)…
  • Abstract Number: 2437 • ACR Convergence 2023

    Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy

    Benjamin Cai1, Rabina Giri2, Helen Benham3, Linda Rehaume1, Geoffery Strutton3, Anne-Sophie Bergot1 and Ranjeny Thomas4, 1Frazer Institute, The University of Queensland, Woolloongabba, Australia, 2Mater Research Institute-UQ, Woolloongabba, Australia, 3Princess Alexandra Hospital, Woolloongabba, Australia, 4Frazer Institute, The University of Queensland, Brisbane, Australia

    Background/Purpose: In spondylarthropathy (SpA), such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS), arthritis is often associated with gut inflammation. After systemic β-1,3-glucan (curdlan) injection,…
  • Abstract Number: 2460 • ACR Convergence 2023

    Health Care Segregation, but Not Metropolitan Area Segregation, Magnifies Racial Disparities in Hospital Outcomes of Pediatric Lupus

    Joyce Chang1, Jessica Liu1, Laura Berbert1, Edie Weller1, Gabrielle Alonzi1, Emily Smitherman2, Pooja Patel3, Mary Beth Son4 and Karen Costenbader5, 1Boston Children's Hospital, Boston, MA, 2University of Alabama at Birmingham, Birmingham, AL, 3Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4Division of Immunology, Boston Children's Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Racial disparities and hospital-level variation in pediatric SLE (pSLE) outcomes are well described, but it is not known how the racial and ethnic composition…
  • Abstract Number: 2464 • ACR Convergence 2023

    B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature

    Erin Wilfong1, Leslie Crofford2 and Rachel Bonami1, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University Medical Center, Melbourne, AR

    Background/Purpose: Autoantibodies directed against various tRNA synthetases defines the anti-tRNA synthetase syndrome (ARS). While it is unclear if the autoantibodies are directly pathogenic, the efficacy…
  • Abstract Number: 2465 • ACR Convergence 2023

    Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen

    Lindsay Bass1, Dena Liu1, Alberto Cisneros2, Jennifer Young-Glazer2, Leslie Crofford3, Erin Wilfong2 and Rachel Bonami2, 1Vanderbilt University, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University Medical Center, Melbourne, AR

    Background/Purpose: Anti-histidyl-tRNA synthetase syndrome (Jo-1 ARS) is defined by the presence of autoantibodies against histidyl tRNA synthetase (Jo-1). Clinically, Jo-1 ARS can involve multiple tissues…
  • Abstract Number: 2459 • ACR Convergence 2023

    Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals

    Idil Eroglu, Hailey Baker, Mario Felix and Lisa Suter, Yale School of Medicine, New Haven, CT

    Background/Purpose: Reporting of race and ethnicity as social constructs is critical to highlight equity and diversity of study participants, with the knowledge that socio-economic factors…
  • Abstract Number: 2405 • ACR Convergence 2023

    Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis

    Despoina Michailidou1, Peter Grayson2, Payton Hermanson1, Jorge Armando Gonzalez-Chapa1, David Cuthbertson3, Nader A. Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Larry Moreland8, Christian Pagnoux9, Philip Seo10, Antoine G Sreih11, Kenneth Warrington12, Paul Monach13, Peter Merkel7 and Christian Lood1, 1University of Washington, Seattle, WA, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 3University of South Florida, Tampa, FL, 4McMaster University, Hamilton, ON, Canada, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania, Philadelphia, PA, 8University of Colorado, Denver, CO, 9Mount Sinai Hospital, Toronto, ON, Canada, 10Johns Hopkins University, Baltimore, MD, 11Bristol Myers Squibb, Princeton Pike, NJ, 12Mayo Clinic, Rochester, MN, 13VA Boston Healthcare System, Boston, MA

    Background/Purpose: We recently found extracellular mitochondrial-derived N-formyl methionine in patients with giant cell arteritis (GCA. Extracellular mitochondria can be extruded by several mechanisms, including platelet…
  • Abstract Number: 2392 • ACR Convergence 2023

    Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis

    andre ramon1, helene Greigert2, corentin Richard3, claudie cladière4, coraline genet5, marion ciudad6, georges tarris7, laurent martin8, louis arnould9, catherine creuzot-garcher10, paul ornetti11, Sylvain Audia12, romain boidot3, jean-Francis Maillefert11, Bernard Bonnotte2 and Maxime Samson2, 1Department of Rheumatology, Dijon University Hospital, Dijon, France, 2Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 3Département de Biologie et de Pathologie des Tumeurs, ICMUB UMR CNRS 6302, Centre Georges François Leclerc, Dijon, France, 4INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, 5INSERM 1098 RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, 6INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, 7Department of Pathology, Dijon-Bourgogne university Hospital, Dijon, France, 8Department of Pathology, Dijon University Hospital, Dijon, France, 9Department of Ophtalmology, Dijon-Bourgogne university Hospital, Dijon, France, 10Department of Ophthalmology, Dijon University Hospital, Dijon, France, 11Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France, 12Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France

    Background/Purpose: Polymyalgia rheumatica (PMR) is associated with giant cell arteritis (GCA) in 16 to 21% of cases. This raises the question of a pathophysiological continuum…
  • Abstract Number: 2255 • ACR Convergence 2023

    Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial

    Kilian Eyerich1, Alice B. Gottlieb2, Stefano Piaserico3, Stefan Beissert4, Melinda Gooderham5, Brian Kirby6, Nicola Tilt7, Cynthia Madden8, Susanne Wiegratz9, Dirk de Cuyper10, Joseph F. Merola11 and Boni Elewski12, 1Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Dermatology Unit, Department of Medicine, Università di Padova, Padova, Italy, 4Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, 5SKiN Centre for Dermatology, Probity Medical Research, Peterborough, ON, Canada, and Queen’s University, Kingston, ON, Canada, 6Elm Park and the Charles Institute, St Vincent's University Hospital, University College Dublin, Dublin, Ireland, 7UCB Pharma, Slough, United Kingdom, 8UCB Pharma, Morrisville, NC, 9UCB Pharma, Monheim am Rhein, Germany, 10UCB Pharma, Brussels, Belgium, 11Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 12Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH

    Background/Purpose: Psoriatic lesions in highly visible areas, including the nails, disproportionately affect patients' health‑related quality of life.[1] Here, we compare the efficacy of bimekizumab (BKZ)…
  • Abstract Number: 2417 • ACR Convergence 2023

    Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study

    LUIGI BOIARDI1, PIERLUIGI MACCHIONI2, Francesco Muratore3, Elena Galli4, chiara marvisi4, caterina Ricordi4, federica Macaluso1, alberto cavazza4, Stefania Croci4 and Carlo Salvarani5, 1IRCCS REGGIO EMILIA, Reggio Emilia, Italy, 2Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, 5Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Few studies have evaluted the influence of histological features of temporal artery biopsy (TAB) on disease outcome in giant cell arteritis (GCA) patients. Our…
  • Abstract Number: 2406 • ACR Convergence 2023

    Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study

    Mohanad Elfishawi1, Mahmut Kaymakci1, Sara Achenbach2, Cynthia Crowson1, Tanaz Kermani3, Cornelia M. Weyand4, Matthew Koster1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, Rochester, MN, 3University of California Los Angeles, Los Angeles, CA, 4Mayo Clinic School of Medicine and Stanford University, Rochester, MN

    Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
  • Abstract Number: 2278 • ACR Convergence 2023

    Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry

    Cristiana Sieiro Santos1, Paula Pérez García2, Jose Ordas Martínez2, Clara Moriano2, Carolina Álvarez Castro2 and Elvira Díez Álvarez2, 1Complejo Asistencial Universitario de León, León, Spain, 2CAULE, León, Spain

    Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
  • Abstract Number: 2444 • ACR Convergence 2023

    Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis

    Eric Morand1, Rachel Cheong2, Peter Eggenhuizen2, Janet Chang2, Ashraf Broury2, Boaz Ng2, Khai Loh2, Elean Tay2, Chanjuan Shen3, Julie Monk2, Yong Zhong4, Steven Lim2, Jia Xi Chung2, Rangi Kandane-Rathnayake5, Rachel Koelmeyer2, Alberta Hoi6, Sarah Snelgrove2, Yi Tian Ting2 and Joshua Ooi2, 1Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, 2Monash University, Clayton, Australia, 3Central South University, Changsha, China, 4Xiangya Hospital, Central South University, Changsha, China, 5Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, 6Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia

    Background/Purpose: Regulatory T cells (Tregs) play an important role in maintaining immune system homeostasis. Antigen-specific Tregs potently and specifically suppress autoreactivity, suggesting their potential to…
  • Abstract Number: 2451 • ACR Convergence 2023

    TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank

    Karen Costenbader1, Zhi Yu2, Emily G. Oakes3, Michelle Robinette4, Mridul Agarwal5, Buu Truong6, Md Mesbah Uddin6, Alexander Bick7, Abhishek Niroula6, Daniel Solomon3 and Pradeep Natarajan8, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Broad Institute; Massachusetts General Hospital, Cambridge, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital; Dana-Farber Cancer Institute, Boston, MA, 5Dana-Farber Cancer Institute, Boston, MA, 6Broad Institute, Cambridge, MA, 7Broad Institute; Vanderbilt University Medical Center, Nashville, TN, 8Broad Institute; Massachusetts General Hospital, Boston, MA

    Background/Purpose: Clonal hematopoiesis (CH), the clonal expansion of somatically mutated blood cells in people without hematologic malignancy, is found in ~10% of people age ≥…
  • Abstract Number: 2472 • ACR Convergence 2023

    Synovitis and the Risk of Incident Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study

    ting Jiang1, Qianlin Weng1, Jiatian Li2, Yuqing Zhang3, Weiya Zhang4, Michael Doherty4, Tuo Yang5, Zidan Yang6, Ke Liu1, Qiu Chen1, Jie Wei7, Guanghua Lei2 and Chao Zeng2, 1Xiangya Hospital, Central South University, Changsha, China, 2Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, 3Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 4Academic Rheumatology, Clinical Sciences Building, University of Nottingham, City Hospital, Nottingham, United Kingdom, 5Department of Health Management Center, Xiangya Hospital, Central South University, Changsha, China, 6Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, 7Health Management Center, Xiangya Hospital Central South University, Changsha, China

    Background/Purpose: Synovitis is a modifiable pathological lesion of hand osteoarthritis (HOA). Although synovitis has been related to the prevalence and symptoms of HOA, it remains…
  • « Previous Page
  • 1
  • …
  • 352
  • 353
  • 354
  • 355
  • 356
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology